Provider Briefing: Bss Ophthalmic Solution Supply in 2026

Balanced Salt Solution (BSS) is a foundational product in ophthalmic surgery. It's used in virtually every cataract extraction, corneal transplant, and anterior segment procedure. When BSS supply tightens, it directly impacts surgical scheduling, patient care, and practice operations.

This article provides a concise, evidence-based briefing for ophthalmologists, surgical center administrators, OR managers, and procurement teams on the current BSS supply landscape, alternatives, and strategies for maintaining uninterrupted surgical operations in 2026.

Timeline: How We Got Here

The BSS supply story begins in 2008, when the FDA issued enforcement actions against multiple manufacturers producing unapproved Balanced Salt Solution products:

• September 2008: The FDA published a Federal Register notice requiring manufacturers of unapproved ophthalmic BSS to cease production. Companies affected included B. Braun, Baxter, and Hospira.
• 2008–2010: Unapproved products were removed from the market, leaving Alcon Laboratories as the primary manufacturer of FDA-approved BSS (BSS Sterile Irrigating Solution) and BSS Plus.
• 2010–2024: The market remained concentrated, with Alcon commanding the majority of BSS supply. Periodic production disruptions — from facility maintenance to raw material shortages — caused intermittent supply constraints.
• 2024–2026: New entrants like ZEISS (Puri Clear BSS) began offering alternatives, but Alcon remains dominant. Supply is adequate in aggregate but regionally variable, with some distributors and surgical centers experiencing periodic backorders.

Prescribing and Procedural Implications

BSS supply constraints affect clinical decision-making in several ways:

Product Selection

Standard BSS Sterile Irrigating Solution is indicated for extraocular and intraocular irrigation during procedures with an expected duration of less than 60 minutes. BSS Plus (enriched with bicarbonate, dextrose, and glutathione) is recommended for longer procedures.

When standard BSS is unavailable, providers should consider:

• BSS Plus: Provides superior corneal endothelial protection and can be used for procedures of any duration. The trade-off is higher cost ($35–$90 per 500 mL vs. $8–$25 per 15 mL for standard BSS).
• Endosol Extra: FDA-approved balanced salt solution for intraocular irrigation. A direct substitute in most clinical scenarios.
• Navstel: Enriched formulation with hypromellose, dextrose, and glutathione. Particularly suitable for complex or prolonged procedures.

Special Populations

The prescribing information for BSS notes that iso-osmotic intraocular irrigating solutions should be used with caution in diabetic patients undergoing vitrectomy, as intraoperative lens changes have been observed. This precaution applies equally to alternative BSS products.

Adverse Event Monitoring

Reports of corneal clouding, edema, and corneal decompensation have been associated with BSS use during surgery. These events may relate to surgical trauma rather than the irrigating solution itself, but providers should document any adverse outcomes and report them through MedWatch.

Current Availability Picture

As of March 2026, the supply situation can be characterized as follows:

• BSS Sterile Irrigating Solution (15 mL, 30 mL): Generally available but subject to periodic backorders from major distributors (McKesson, Cardinal Health, Medline). Lead times can extend from days to 2–3 weeks during constrained periods.
• BSS Plus (500 mL): More consistently available than standard BSS, but at higher cost. Most large ASCs and hospital systems maintain adequate supply.
• Generic Balanced Salt Solution: Available from multiple manufacturers for institutional purchasers at $15–$50 per 500 mL. Confirm FDA-approval status before procurement, as some products on the market may not have full NDA/ANDA approval.
• ZEISS Puri Clear BSS: An emerging option from a major ophthalmic equipment manufacturer, gradually gaining distribution in the U.S. market.

Cost and Access Considerations

BSS is typically covered as part of the surgical facility fee under medical insurance, with no separate patient copay or prior authorization. Key cost considerations for practices:

• Standard BSS (15 mL): $8–$25 per unit
• BSS Plus (500 mL): $35–$90 per unit
• Generic BSS (500 mL): $15–$50 per unit for institutional purchasers

During shortage periods, some distributors may raise prices or require minimum order quantities. Practices should monitor procurement costs and consider negotiating contracts that include supply guarantees.

Surgical centers operating on thin margins should evaluate whether stocking a mix of standard BSS and BSS Plus provides better supply resilience than relying on a single product.

Tools and Resources for Providers

Medfinder for Providers offers tools specifically designed for healthcare professionals managing drug and supply shortages:

• Real-time availability tracking: Search for BSS products across multiple distributors and surgical supply sources.
• Shortage alerts: Receive notifications when BSS supply status changes in your region.
• Alternative product information: Quick-reference guides for BSS alternatives with clinical comparison data.

Additional resources:

• FDA Drug Shortage Database: accessdata.fda.gov/scripts/drugshortages
• ASHP Drug Shortage Resource Center: ashp.org/drug-shortages
• American Academy of Ophthalmology: Practice advisories on surgical supply management

Looking Ahead

Several developments may improve the BSS supply landscape in the coming years:

• Market diversification: The entry of ZEISS and other manufacturers is gradually reducing dependence on a single supplier.
• FDA regulatory pathways: The FDA's Reference Listed Drug designations for BSS, BSS Plus, and Endosol Extra allow abbreviated new drug applications (ANDAs), which could accelerate generic market entry.
• Improved procurement strategies: More surgical centers are adopting multi-source procurement approaches and maintaining buffer inventory to ride out short-term disruptions.

However, the fundamental market structure — high demand, limited manufacturers, complex sterile manufacturing requirements — means that periodic supply tightness is likely to persist through 2026 and beyond.

Final Thoughts

BSS supply management requires the same proactive approach that practice leaders apply to other critical surgical supplies. Build relationships with multiple distributors, maintain buffer inventory, stay informed about alternative products, and use tools like Medfinder for Providers to monitor real-time availability.

For patient-facing information you can share with surgical candidates concerned about BSS availability, direct them to our article: Bss Ophthalmic Solution Shortage Update: What Patients Need to Know in 2026.

And for a practical guide on helping patients navigate the supply landscape, see How to Help Your Patients Find Bss Ophthalmic Solution in Stock: A Provider's Guide.